• Dash Bio raised USD 30 million in a Series A round led by Oak HC/FT, lifting total funding to USD 47.5 million.
• The company builds a GLP-compliant bioanalysis platform aimed at speeding drug development by automating lab testing and digitizing workflows.
• Dash Bio operates a 24,000-square-foot laboratory using robotics and proprietary software to cut turnaround times from months to days.
• Proceeds will fund commercial expansion, increased lab capacity, a broader assay menu, entry into new categories, and continued software development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oak HC/FT Partners LP published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.